Current Pharmaceutical Design - Volume 22, Issue 23, 2016

Background: Histone Deacetylase (HDAC) enzymes in the human body play an important role in the transcriptional regulation of gene expression. In the last decade, HDAC inhibitors and activators have been explored and have become known as therapeutic agents for many diseases such as osteodystrophy, neurogenerative disorders, cardiomyopathy, cancer, and diabetes. In recent years, the development of HDAC inhibitors Read More

Background: Many factors that directly or indirectly cause adverse drug reaction (ADRs) varying from pharmacological, immunological and genetic factors to ethnic, age, gender, social factors as well as drug and disease related ones. On the other hand, advanced methods of statistics, machine learning and data mining allow the users to more effectively analyze the data for descriptive and predictive purposes. The fast changes i Read More

Background: A major class of chemotherapy drugs targets the genome of cancer cells. These DNA damaging agents induce damage to the DNA helix, resulting in the programmed death of cancer cells. An overactivated DNA repair mechanism in cancer cells can reduce the efficacy of these drugs, thereby eliminating their therapeutic benefit and developing an acquired resistance to these otherwise effective drugs. A promisi Read More

Background: The influenza virus is one of the most critical threats to public health with major economic impact. Though annual influenza vaccination is currently the most effective prevention strategy against flu epidemics and pandemics, the mutational evolution of the influenza virus tends to reduce the effectiveness of strain-specific vaccines. Methods: For past decades, a broad spectrum of potentially universal influe Read More

Background: Computer-aided drug design is still a state-of-the-art process in medicinal chemistry, and the main topics in this field have been extensively studied and well reviewed. These topics include compound databases, ligand-binding pocket prediction, protein-compound docking, virtual screening, target/off-target prediction, physical property prediction, molecular simulation and pharmacokinetics/pharmacodynam Read More

Background: Drug discovery is one important issue in medicine and pharmacology area. Traditional methods using target-based approach are usually time-consuming and ineffective. Recently, the problems are approached in a system-level view and therefore it is called systems pharmacology. This research field deals with the problems in drug discovery by integrating various kinds of biomedical and pharmacolog Read More

The drug discovery process in general is a very resource intensive undertaking that has existed for a very long time. In the last two decades, performing molecular simulations that determine the level of interaction between a protein and ligand have been refined to the point where they are now an essential part of the drug discovery process. These simulations serve to reduce the time to discovery and improve the positi Read More

Discovery of new therapeutics is a very challenging, expensive and time-consuming process. With the number of approved drugs declining steadily, combined with increasing costs, a rational approach is needed to facilitate, expedite and streamline the drug discovery process. In silico methods are playing key roles in the discovery of a growing number of marketed drugs. The use of computational approaches, particularly molec Read More

Background: The human islet amyloid polypeptide (hIAPP) can form insoluble fibrillar aggregates in the pancreas of patients with type 2 diabetes. However, increasing evidence suggests that, rather than the fibrils themselves, the hIAPP oligomers that appear on the fibrillation pathway are the toxic species for the pancreatic β -cells. In the perspective of designing therapeutic inhibitors of hIAPP aggregation, it is thus crucial to b Read More

Background: Metabolic syndromes such as insulin resistance, type 2 diabetes and obesity share common pathogenic pathways with some age-related neurodegenerative disorders. Impaired insulin signaling, inflammation, mitochondrial dysfunction and ER stress can be both causatives and consequences in both groups of the diseases. Patients with chronic metabolic disorders therefore have potential risks to develop neurolo Read More